Literature DB >> 8792428

In vivo assessment of intestinal, hepatic, and pulmonary first pass metabolism of propofol in the rat.

A A Raoof1, P F Augustijns, R K Verbeeck.   

Abstract

PURPOSE: The relative contribution of the intestinal mucosa, liver and lung to the in vivo disposition of propofol in the rat was investigated.
METHODS: Propofol (4.9-5.1 mg.kg-1) was administered to groups of rats (n = 4) via the intra-arterial, intravenous, hepatic portal venous and oral routes. The AUC's of propofol were estimated and the fractions of the administered dose escaping first pass metabolism by the gut wall (fG), liver (fH) and lung (fL) were calculated. In addition, transport experiments were carried out using Caco-2 cell monolayers to rule out the possibility that intestinal permeability is limiting the oral absorption of propofol.
RESULTS: Values for fG, fH and fL were the following: 0.21 +/- 0.07, 0.61 +/- 0.13, and 0.82 +/- 0.09, respectively. The apparent permeability coefficient of propofol across Caco-2 cell monolayers was 24.2 +/- 0.3 x 10(-6) cm.sec-1, which is similar to the apparent permeability coefficient obtained for propranolol (30.7 +/- 1.7 x 10(-6) cm.sec-1), a compound known to easily cross the intestinal epithelial membranes. The formation of propofol glucuronide, a major metabolite of propofol, could not be demonstrated during the flux experiments across the Caco-2 cell monolayers.
CONCLUSIONS: The intestinal mucosa is the main site of first pass metabolism following oral administration of propofol in the rat. Intestinal metabolism could therefore also contribute to the systemic clearance of propofol.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8792428     DOI: 10.1023/a:1016057229478

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  16 in total

1.  Evidence for glucuronide conjugation of p-nitrophenol in the Caco-2 cell model.

Authors:  S Bjorge; K L Hamelehle; R Homan; S E Rose; D A Turluck; D S Wright
Journal:  Pharm Res       Date:  1991-11       Impact factor: 4.200

2.  Hepatic and extrahepatic disposition of propofol in patients undergoing coronary bypass surgery.

Authors:  H Lange; H Stephan; H Rieke; M Kellermann; H Sonntag; J Bircher
Journal:  Br J Anaesth       Date:  1990-05       Impact factor: 9.166

3.  Improved method for the determination of propofol in blood by high-performance liquid chromatography with fluorescence detection.

Authors:  G F Plummer
Journal:  J Chromatogr       Date:  1987-10-09

4.  Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability.

Authors:  I J Hidalgo; T J Raub; R T Borchardt
Journal:  Gastroenterology       Date:  1989-03       Impact factor: 22.682

5.  Comparison of intestinal permeabilities determined in multiple in vitro and in situ models: relationship to absorption in humans.

Authors:  B H Stewart; O H Chan; R H Lu; E L Reyner; H L Schmid; H W Hamilton; B A Steinbaugh; M D Taylor
Journal:  Pharm Res       Date:  1995-05       Impact factor: 4.200

6.  Extrahepatic metabolism of propofol in man during the anhepatic phase of orthotopic liver transplantation.

Authors:  P Veroli; B O'Kelly; F Bertrand; J H Trouvin; R Farinotti; C Ecoffey
Journal:  Br J Anaesth       Date:  1992-02       Impact factor: 9.166

7.  Permeability enhancement in Caco-2 cell monolayers by sodium salicylate and sodium taurodihydrofusidate: assessment of effect-reversibility and imaging of transepithelial transport routes by confocal laser scanning microscopy.

Authors:  M A Hurni; A B Noach; M C Blom-Roosemalen; A G de Boer; J F Nagelkerke; D D Breimer
Journal:  J Pharmacol Exp Ther       Date:  1993-11       Impact factor: 4.030

8.  Distribution of UDP-glucuronosyltransferase and its endogenous substrate uridine 5'-diphosphoglucuronic acid in human tissues.

Authors:  M Cappiello; L Giuliani; G M Pacifici
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 9.  Propofol. An update of its use in anaesthesia and conscious sedation.

Authors:  H M Bryson; B R Fulton; D Faulds
Journal:  Drugs       Date:  1995-09       Impact factor: 9.546

10.  Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells.

Authors:  P Artursson
Journal:  J Pharm Sci       Date:  1990-06       Impact factor: 3.534

View more
  6 in total

1.  Species differences in stereoselective hydrolase activity in intestinal mucosa.

Authors:  Y Yoshigae; T Imai; A Horita; H Matsukane; M Otagiri
Journal:  Pharm Res       Date:  1998-04       Impact factor: 4.200

2.  Age progression from vicenarians (20-29 year) to nonagenarians (90-99 year) among a population pharmacokinetic/pharmacodynamic (PopPk-PD) covariate analysis of propofol-bispectral index (BIS) electroencephalography.

Authors:  Ashraf A Dahaba; Zhaoyang Xiao; Xiaoling Zhu; Hailong Dong; Lize Xiong; Peter Rehak; Sieglinde Zelzer; Kun Wang; Gilbert Reibnegger
Journal:  J Pharmacokinet Pharmacodyn       Date:  2020-02-25       Impact factor: 2.745

3.  Gastrointestinal delivery of propofol from fospropofol: its bioavailability and activity in rodents and human volunteers.

Authors:  Krystyna M Wozniak; James J Vornov; Bipin M Mistry; Ying Wu; Rana Rais; Barbara S Slusher
Journal:  J Transl Med       Date:  2015-05-29       Impact factor: 5.531

Review 4.  Predicting Drug Extraction in the Human Gut Wall: Assessing Contributions from Drug Metabolizing Enzymes and Transporter Proteins using Preclinical Models.

Authors:  Sheila Annie Peters; Christopher R Jones; Anna-Lena Ungell; Oliver J D Hatley
Journal:  Clin Pharmacokinet       Date:  2016-06       Impact factor: 6.447

Review 5.  Metabolic Profiles of Propofol and Fospropofol: Clinical and Forensic Interpretative Aspects.

Authors:  Ricardo Jorge Dinis-Oliveira
Journal:  Biomed Res Int       Date:  2018-05-24       Impact factor: 3.411

Review 6.  Clinical Pharmacokinetics and Pharmacodynamics of Propofol.

Authors:  Marko M Sahinovic; Michel M R F Struys; Anthony R Absalom
Journal:  Clin Pharmacokinet       Date:  2018-12       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.